Venous Thrombotic Recurrence After Cerebral Venous Thrombosis. A Long-Term Follow-Up Study
|
|
- Erika Andrews
- 5 years ago
- Views:
Transcription
1 Venous Thrombotic Recurrence After Cerebral Venous Thrombosis A Long-Term Follow-Up Study Paola Palazzo, MD, PhD*; Pierre Agius, MD*; Pierre Ingrand, MD; Jonathan Ciron, MD; Matthias Lamy, MD; Aline Berthomet, MD; Paul Cantagrel, MS; Jean-Philippe Neau, MD Background and Purpose After cerebral venous thrombosis (CVT), the risk of venous thrombotic events was estimated at 2% to 3% for a new CVT and 3% to 8% for extracranial events. However, because of the paucity of prospective studies, the clinical course of CVT is still largely unknown. We aimed to prospectively evaluate the rate of thrombosis recurrence in a cohort of CVT patients with a long-term follow-up and to detect predisposing factors for recurrence. Methods Consecutive CVT patients with complete clinical, radiological, biological, and genetic data were systematically followed up. New venous thrombotic events were detected after hospital readmission and imaging confirmation. Results One-hundred eighty-seven patients (mean age 45±18 years, 67% women) with angiographically confirmed CVT were included. Cause was found in 73% of patients. Coagulation abnormality and JAK2 gene mutation were detected in 20% and 9%, respectively. Median follow-up length was 73 months (range months). Mean duration of the oral anticoagulant treatment was 14 months. Mortality rate was 2.5% per year, with 2% in-hospital mortality. During follow-up, CVT reoccurred in 6 patients, whereas 19 subjects had a symptomatic extracranial venous thrombotic event, with cumulative venous thrombotic recurrence rates of 3% at 1 year, 8% at 2 years, 12% at 5 years, and 18% at 10 years. A previous venous thrombotic event (hazard ratio, 2.8; P=0.018), presence of cancer or malignant hemopathies (hazard ratio, 3.2; P=0.039), and unknown CVT causes (hazard ratio, 2.81; P=0.024) were independently associated with recurrence. Conclusions In our cohort of CVT patients followed on average for >6 years, subjects with a previous venous thrombotic event, cancer/malignant hemopathies, and unknown CVT causes were found to be at higher risk of recurrence. (Stroke. 2017;48: DOI: /STROKEAHA ) Key Words: female mutation risk thrombophilia venous thromboembolism Cerebral venous thrombosis (CVT) is an uncommon disease that mainly affects subjects younger than 40 years of age, patients with thrombophilia, and women who are pregnant or receiving hormonal contraceptives. The annual incidence is estimated to be 3 to 4 cases per million, 1 which increases to 12 cases per deliveries during the peripartum period. 2 Mortality and recurrence rates are lower when compared with arterial stroke, with an estimated annual risk of new venous thrombotic events after a first CVT at 2% to 3% for a new CVT and 3% to 8% for extracranial events. 3 5 However, because of a paucity of prospective studies with long-term follow-up, recurrence of venous thrombosis (VT) after CVT is still largely unknown, as are predisposing factors for recurrence. In fact, mixed results exist on the factors associated with recurrence risk. In a multicenter observational study of 624 adult patients with CVT, male sex and polycythemia/thrombocythemia were found to be the only independent predictors of venous thromboembolism after CVT. 6 These results were not confirmed by other authors who observed an association between recurrence and a history of previous extracerebral venous thrombotic events, 7 whereas in another study no variable was found to be significantly associated with recurrent VT. 4 No study to date has estimated risk of VT recurrence with different CVT causes. We, therefore, aimed to prospectively evaluate the incidence of recurrent cerebral and extracerebral venous thrombotic events in a cohort of CVT patients and to detect clinical, biological, and radiological factors associated with VT recurrence. Methods A database was established to prospectively follow up a cohort of consecutive patients with a first episode of angiographically proven CVT Received September 2, 2016; final revision received November 3, 2016; accepted November 10, From the Department of Neurology, Poitiers University Hospital and University of Poitiers, France (P.P., P.A., J.C., M.L., A.B., P.C., J.-P.N.); Department of Neurology, S. Giovanni Calibita-Fatebenefratelli Hospital, Rome, Italy (P.P.); and Clinical Investigation Center INSERM CIC-P 802, Poitiers University Hospital, France (P.I.). *Drs Palazzo and Agius contributed equally. Correspondence to Paola Palazzo, MD, PhD, Department of Neurology, Poitiers University Hospital, 2 rue de la Milétrie, Poitiers, France. paola.palazzo@chu-poitiers.fr; ppalazzo@hotmail.it 2016 American Heart Association, Inc. Stroke is available at DOI: /STROKEAHA
2 322 Stroke February 2017 admitted to primary (n=3) and comprehensive (n=1) stroke centers in the French Poitou-Charentes region (1.8 million inhabitants, mean age 42 years, 48% <40-year old, 51% women) from January 2005 to December The study was approved by the local ethics committee, and all enrolled subjects signed informed consent forms. Clinical diagnosis of CVT was confirmed by brain computed tomography (CT) with CT venography, magnetic resonance imaging combined with magnetic resonance venography, conventional angiography, or multimodal imaging. Complete clinical, radiological, biological, and genetic data were collected, including demographic data, symptoms and signs from onset to diagnosis, Glasgow Coma Scale and National Institutes of Health Stroke Scale scores in the acute phase, thrombus localization, and presence of parenchymal lesions. Thrombophilic screening was assessed in all the study subjects, including factor V Leiden, G20210A mutations, lupus anticoagulant, and anticardiolipin antibodies. However, proteins C and S and antithrombin III were not systematically assessed before anticoagulation was started and not controlled after treatment interruption; therefore, they were not analyzed in this study. Patients underwent lumbar puncture unless contraindicated. The JAK2 V617F mutation analysis was systematically assessed in all subjects included from 2008 using a real-time polymerase chain reaction method. Follow-up visits were performed at 6 months, including neuroimaging follow-up, at 12 months, and yearly thereafter at outpatient evaluation that included neurological examination. If in-person evaluation was impossible, alternative methods included a telephone interview of the patient or an interview with a relative or general practitioner. Subjects known to be hospitalized for any reason during follow-up underwent direct inpatient neurological evaluation. Follow-up data recorded included: disability (modified Rankin Scale), death, recurrent symptomatic CVT (new symptoms with new thrombosis on repeated neuroimaging), and other symptomatic venous thrombotic events. Primary outcome was cerebral or extracranial VT recurrence. All the new venous thrombotic events were detected after readmission to regional and received imaging confirmation. In case of multiple recurrences, only the first one was included in the time-toevent analysis. Clinically suspected deep vein thrombosis (DVT) was confirmed by duplex ultrasonography, CT, or magnetic resonance imaging venography. Symptomatic pulmonary embolism (PE) was confirmed by contrast-enhanced CT or ventilation perfusion lung scan interpreted as high probability for PE. Symptomatic portal vein thrombosis was confirmed by contrast-enhanced CT or duplex ultrasonography. A recurrent CVT was distinguished from the original thrombosis by comparing serial imaging. To be classified as a recurrent CVT, new or recurrent symptoms had to develop with new filling defects in the follow-up study not present in the first images or in an interval study showing thrombus resolution. Statistical Analyses The Kaplan Meier product-limit method was used to calculate cumulative recurrence rates and SE. Cox proportional hazards models were used for univariate and multivariate prognostic analyses. All variables with a P value <0.2 at univariate analysis were entered in the multivariate analysis. The final model was obtained after applying a backward elimination procedure; all variables with a P value <0.05 were retained. All analyses were performed with SAS release 9.3 software. Results One-hundred ninety-four patients with confirmed CVT were enrolled in our prospective observational study. Seven (3.6%) patients were lost to follow-up after discharge and excluded from the study. Of the remaining 187 patients (mean age 45±18 years, 67% women, 97% white), 98% had an admission Glasgow Coma Scale score between 9 and 15, and 2% were comatose (Glasgow Coma Scale score of <9). Sixty-two patients (33%) presented with isolated intracranial hypertension. Lumbar puncture was performed in 99 patients: 20 patients had >5 cells and 47 had >45 mg/dl protein. Demographic, clinical, and imaging features are shown in Table 1. CVT cause was found in 73% of subjects (Table 2). Genetic or acquired thrombophilia was detected in 20% of subjects, mainly represented by factor V or II mutation. JAK2 gene analysis was assessed in 120 patients, and a mutation was detected in 9% (n=11) of them. A pharmacological cause was observed in 47% of patients, mainly (91%) represented by hormonal contraceptives or replacement therapy and less frequently by chemotherapy. In the acute phase, 185 (99%) patients were anticoagulated with intravenous heparin (94%) or subcutaneous low-molecular weight heparin (6%) in therapeutic dosages followed by oral vitamin K antagonists with a target international normalized ratio of 2:3. 8 One patient was treated with local endovascular thrombolysis, and 1 underwent mechanical thrombectomy. Jugular vein stenting was performed in 2 patients, and 1 had optic nerve fenestration. Additional treatment included antiepileptic medication (59 patients [32%]), mannitol (13 [7%]), and acetazolamide (22 [12%]). Mean and median follow-up lengths were 80 (SD 60) and 73 months (range months), respectively. Patients received oral anticoagulant treatment for 14 months on average. Mortality rate was 2.5% per year with 2% in-hospital mortality and 17% overall mortality, mainly related to cancer or hematologic malignancies. Discharge modified Rankin Scale score was 0 to 1 in 74% of patients, whereas 8% of them had a slight residual disability (modified Rankin Scale score of 2) and 16% moderate to severe disability (modified Rankin Scale score of 3 5). During follow-up, 30 new venous thrombotic events occurred in 25 CVT patients. CVT reoccurred in 6 patients, whereas 19 subjects had new extracranial venous thrombotic events, represented by DVT (12 patients), PE (5 patients), and portal vein thrombosis (2 patients). A single new event occurred in 23 patients, whereas 1 patient experienced CVT followed by PE, and 1 had 5 episodes of DVT. The first recurrent event was included in the analysis. The cumulative venous thrombotic recurrence rate was 3±1% at 1 year, 8±2% at 2 years, 12±3% at 5 years, and 18±4% at 10 years. Recurrence rate is represented in Figure. In patients with a new CVT, mean recurrence delay was 28.5 months (SD 19.7). In 1 of the 6 patients with a recurrent CVT and 1 of the 19 patients with a new extracranial venous thrombotic event (PE), mortality was directly attributable to the recurrence. In univariate analysis, recurrence was associated with older age, a previous venous thrombotic event, absence of hormonal agents, presence of cancer or malignant hemopathy, and unknown causes (Table 3). In addition, patients who discontinued estrogens after CVT displayed decreased recurrence rates compared with subjects who had not taken hormonal treatment (P=0.0036). No association was found between the duration of anticoagulation treatment and the recurrence risk in the overall study population (P=0.70) or the subgroup of patients with CVT of undetermined cause (P=0.30).
3 Palazzo et al Venous Thrombotic Recurrence After CVT 323 Table 1. Demographic, Clinical, Biological, and Radiological Characteristics of the Study Cohort n=187 Age at first CVT, mean (SD), y 45 (18) Female sex 126 (67) BMI, mean (SD) 25 (7) Current smoking 54 (29) Diabetes mellitus 7 (4) Previous stroke 4 (2) CAD 7 (4) Dyslipidemia 28 (15) Arterial hypertension 42 (22) Hyperhomocysteinemia* 26 (28) Previous VTE 24 (13) Family history of VTE 38 (20) History of miscarriages 19 (15) Clinical presentation Asymptomatic 3 (2) Altered mental status 17 (9) Headache 167 (89) Focal deficits 66 (35) Intracranial hypertension 102 (55) Seizures 55 (29) GCS score, mean (SD) 14.6 (0.3) NIHSS score, mean (SD) 3.5 (0.5) Clinical onset delay 7 d 111 (59) 7 21 d 45 (24) 21 d 31 (17) Neuroimaging Occluded sinus number, mean (SD) 2.4 (2.4) Site of thrombosis Superior sagittal sinus 94 (50) Inferior sagittal sinus 12 (6) Right lateral sinus 87 (46) Left lateral sinus 81 (43) Straight sinus 28 (15) Cortical veins 16 (9) Vein of Galen 13 (7) Internal cerebral veins 10 (5) Cavernous sinus 3 (2) Torcular Herophili 28 (15) Left jugular vein 26 (14) Right jugular vein 27 (14) (Continued ) Table 1. Continued n=187 Any parenchymal lesion 78 (42) Ischemic lesions 72 (39) Hemorrhagic lesions 60 (32) Edema 56 (30) Laboratory exams Hemoglobin, g/dl, mean, (SD) 13.4 (2) Platelets, giga/l, mean, (SD) 266 (109) Thrombophilia testing Factor V mutation 14 (8) Factor II mutation 18 (11) JAK2 mutation 11 (9) Anti-β2-GP1 antibodies 1 (0.6) Anticardiolipin antibodies 4 (2) Data are expressed as n(%) unless specified. BMI indicates body mass index; CAD, coronary artery disease; CVT, cerebral venous thrombosis; GCS, Glasgow Coma Scale; NIHSS, National Institutes of Health Stroke Scale; and VTE, venous thrombotic events. *Homocysteine was tested in 94 subjects (50%); percentage was calculated in this subgroup. Percentage calculated in the female subgroup. Evaluated in 173 subjects (93%); percentage was calculated in this subgroup. Evaluated in 167 subjects (89%); percentage was calculated in this subgroup. Evaluated in 120 subjects (64%); percentage was calculated in this subgroup. When all potential risk variables with P value <0.2 at univariate analysis were entered into multivariate model, a previous venous thrombotic event (hazard ratio [HR], 2.8; P=0.018), presence of cancer or malignant hemopathy (HR, 3.2; P=0.039), and unknown CVT cause (HR, 2.81; P=0.024) were independently associated with any first VT recurrence (Table 3). Table 2. Cerebral Venous Thrombosis Causes in the Study Population n=187 Cryptogenic 51 (27) Recent trauma 9 (5) CNS infection 29 (16) Chronic inflammatory disease 9 (5) Cancer 10 (5) Malignant hemopathies 19 (10) Thrombophilic abnormalities 37 (20) Recent/ongoing chemotherapy 8 (4) OC* 72 (57) HRT* 7 (6) Pregnancy* 3 (2) Postpartum* 1 (1) Data are expressed as n (%). Forty-seven (25%) patients had >1 known risk factor for cerebral venous thrombosis. CNS indicates central nervous system; HRT, hormone replacement therapy; and OC, oral contraceptives. *Percentage calculated in the female subgroup.
4 324 Stroke February 2017 Table 3. Association of Baseline Characteristics and Potential Risk Factor for Recurrent VTE at Univariate and Multivariate Analyses Variables HR 95% CI P Value Univariate analysis Age, 1-y increment 1.03 ( ) Sex, female vs male 1.31 ( ) Previous VTE 3.50 ( ) Thrombophilia 0.86 ( ) 0.75 Infection 1.04 ( ) 0.95 Cancer+hemopathies 2.30 ( ) Pregnancy+postpartum (n=126) 4.40 ( ) OC+HRT (n=126) 0.25 ( ) Unknown cause 2.37 ( ) Multivariate analysis Figure. Kaplan Meier curve of venous thrombosis recurrence rate. Discussion Our study showed that cumulative risk of recurrent VT continues to increase over time. We also detected factors associated with VT recurrence in subjects who were diagnostically evaluated and treated for the initial CVT. Early recurrence rates in our study are comparable with the results of other studies. 3 5,7,9 11 Details on the studies that evaluated venous thrombotic events recurrence in CVT patients are displayed in Table 4. In the ISCVT study (International Study on Cerebral Vein and Dural Sinus Thrombosis), a large prospective multinational observational study conducted on 624 adult cases of CVT, a 2.2% overall CVT recurrence rate and 3% extracranial venous thrombotic recurrence rate were observed Table 4. Summary of Studies That Evaluated VTE Recurrence in CVT Patients Previous VTE 2.82 ( ) Cancer+hemopathies 3.24 ( ) Unknown cause 2.81 ( ) CI indicates confidence interval; HR, hazard ratio; HRT, hormone replacement therapy; OC, oral contraceptive; and VTE, venous thrombotic events. during a median follow-up period of 16 months (mean=18.6, SD=11.1). 3 Ruling out subjects lost to follow-up immediately after discharge (n=80), cerebral and extracerebral venous thrombotic recurrence rates were 2.6% and 3.4%, respectively. Similarly, Gosk-Bierska et al 4 found a 2.2% annual sinus thrombosis recurrence rate and a 2.8% annual extracerebral thrombosis (ie, DVT or PE) recurrence rate during a mean follow-up period of 36±47 months (range months) after a CVT, with a median time to recurrence of 10 months. Author Year of Publication Country Study Design Setting Subjects, n Median/ Mean FU Definition of Recurrence Preter et al France Retrospective Tertiary center y Interview or questionnaire Ferro et al 10 Tertiary centers and community 2002 Portugal Mixed y Clinical visit or interview Gosk-Bierska et al United States Retrospective Tertiary center y Clinical visit Miranda et al Multinational Prospective Tertiary centers and community y Clinical visit Martinelli et al Italy Prospective Tertiary center y Clinical visit or interview Dentali et al Multinational Retrospective Tertiary centers and community y Clinical visit or interview or questionnaire and hospital records Hiltunen et al Finland Retrospective Tertiary center y Questionnaire Present study 2016 France Prospective Tertiary center and community y Clinical visit or interview
5 Palazzo et al Venous Thrombotic Recurrence After CVT 325 An annual CVT recurrence rate of 1.8% was observed by Preter et al 9 in 77 patients with CVT during a median followup period of 63 months, mainly (89%) occurred within the first 12 months, whereas in the VENOPORT study (Cerebral Venous Thrombosis Portuguese Collaborative Study Group), a 1.6% overall CVT recurrent thrombosis rate was reported in 126 CVT patients with a mean follow-up length of 1.8 years. 10 Similarly, Martinelli et al 5 found an event rate of 2.03 per 100 patient-years in a population of 145 patients with a first episode of CVT followed up for 6 years after discontinuation of anticoagulant therapy. In a large, retrospective cohort study, an overall recurrence incidence of 23.6 events per 1000 patient-years (95% confidence interval [CI], ) was observed during a median follow-up period of 40 months (range months). 7 Recently, in a retrospective single-center study conducted on 161 CVT patients with a median follow-up period of 39 months (interquartile range months), Hiltunen et al 11 observed a 1.1% annual venous thromboembolic recurrence rate (5 DVT, 2 PE, and 3 superficial vein thrombosis) with a 0.1% annual CVT recurrence rate. Authors stated that low incidence of recurrence could be explained by the frequent use of antithrombotic agents in this study population because 39% of patients received permanent anticoagulation and 25% received aspirin. Similarly to other studies, in our population, new venous thrombotic events mainly (52%) occurred in the first 24 months. In our cohort of CVT patients with long-term follow-up, subjects with a previous venous thrombotic event, presence of cancer or malignant hemopathies, and unknown CVT causes were found to be at higher risk of recurrence in the multivariate analysis. The increased risk of both cerebral and extracerebral venous thrombotic recurrence in CVT patients with a history of previous extracerebral venous thrombotic events (HR, 2.70; Cerebral/Extracerebral VTE Annual Recurrence Rate 95% CI, ; P<0.011) has previously been observed by Dentali et al, 7 while the association with cancer was found only in the univariate analysis. On the contrary, in the ISCVT, male sex (HR, 2.6; 95% CI, ; P=0.004) and polycythemia/thrombocythemia (HR, 4.4; 95% CI, ; P=0.005) were the only independent predictors of venous thromboembolism after CVT. 6 Similarly, in the study conducted by Martinelli et al, 5 male CVT patients had a 7- to 8-fold increased risk of recurrence compared with female patients, while severe thrombophilia was associated with an increased risk of DVT or PE (HR, 4.71; 95% CI, ), but not with CVT recurrence. However, these findings may not be applicable to the general CVT population because patients with malignancies or in need of permanent anticoagulation were not included in this study. Differences in the inclusion criteria might be the reason of the discrepancy between our results and those of the Italian group because we did not find any correlation between sex and recurrence risk. In the study by Gosk-Bierska et al, 4 no variable was found to be significantly associated with recurrent VT, whereas Hiltunen et al 11 did not specifically address this issue. To our knowledge, this is the first time that cryptogenic CVT was found to be associated with the risk of recurrence. The prospective design and long-term follow-up of our study might explain this difference. Our cryptogenic CVT rate is similar to that reported in other studies; however, a wide range of idiopathic thrombosis rates, from 9% to 44%, has been reported. 3 5,7,11 In our opinion, unknown causes may limit secondary prevention measures in this subgroup of patients, leading to an increase in the risk of recurrence. This finding underscores the need for further research to better identify both congenital and acquired VT risk factors to develop more specific treatment strategies. Another finding of our study is that women receiving hormonal agents such as oral contraceptives or replacement therapy Thrombophilia Testing Reported New Cerebral/Extracerebral VTE Factors Associated With VTE Recurrence 1.8%/* Not specified 9 CVT* NA NA Incomplete 2 CVT2 DVT1 PE NA 2.2%/2.8% Complete 23 VTE occurred in 20 subjects: 10 CVT, 8 DVT, and 5 PE No associated factors 1.5%4.1% overall VTE annual recurrence rate Incomplete 38 VTE occurred in 36 subjects: 14 CVT, 16 DVT, 4 PE, 3 upper limb DVT, and 1 mesenteric venous thrombosis Male sex; polycythemia/ thrombocythemia 0.53%/1.05% Complete 15 VTE occurred in 15 subjects: 5 CVT, 8 DVT, and 2 PE Male sex; severe thrombophilia 2.4% overall VTE annual recurrence rate 0.1%/1.1% Not specified 0.5%/1.7% Incomplete Incomplete 77 VTE occurred in 75 subjects: 31 CVT and 46 extracerebral VTE Previous extracerebral VTE; cancer 9 VTE occurred in 9 subjects: 1 CVT, 5 DVT, 2 PE, and 3 Superficial vein thrombosis 30 VTE occurred in 25 subjects: 6 CVT, 16 DVT, 6 PE, and 2 Portal vein thrombosis NA Previous VTE; cancer, malignant hemopathies, or JAK2 mutation; unknown CVT causes CVT indicates cerebral venous thrombosis; DVT, deep vein thrombosis; FU, follow-up; PE, pulmonary embolism; NA, not assessed; and VTE, venous thrombotic events. *Not known the exact number/incidence of new extracerebral VTE (11 arterial or venous extracerebral events). Association found only in the univariate analysis.
6 326 Stroke February 2017 at the time of their first CVT event had lower recurrence risk compared with women who had not taken estrogens. These data suggest that subjects whose CVT is favored by hormonal agents are at lower risk of new venous thrombotic events after estrogen discontinuation compared with CVT patients with other risk factors or whose CVT cause was not detected. Similar data were obtained in a study conducted on patients with a first event of DVT and PE; a trend toward a lower risk of recurrence after discontinuation of oral contraceptive was observed compared with subjects who had not taken estrogens, although this result was not confirmed for postmenopausal hormones. 12 One limitation of our study is that we included patients with incomplete thrombophilia evaluation. In fact, because of a relatively high percentage of subjects whose thrombophilic screening was not repeated after anticoagulation interruption, a decision was made to only consider clear prothrombotic abnormalities. As a consequence, idiopathic CVT percentage may have been slightly overestimated. However, because of the rigorous selection process and considering the robust statistical results, we think that our findings were not significantly affected. Another limitation is that, because of the low number of female subjects under replacement therapy before CVT, we cannot exclude the possibility that the significant association between hormonal agents and recurrence risk was mainly driven by oral contraceptives more than by postmenopausal hormones. A third limitation is that our study is a French single-region study, which almost exclusively included white patients; we cannot rule out the possibility that our results were influenced by genetic and environmental factors and, therefore, should be verified in different populations before being applied to other contexts. However, this design assures better homogeneity in selection and follow-up procedures. A forth limitation is represented by the higher cancer and hematology malignancy prevalence compared with previous follow-up study populations; this probably explains the relatively high mortality rate during follow-up. However, a decision was made to include all consecutive subjects with a first CVT event and at least 1 follow-up evaluation, including those with malignancies, to better evaluate recurrence rate in the global CVT population. Finally, it is worth specifying that all new qualifying events, including PE, occurred after CVT resolution at follow-up imaging and should thus be considered as new events and not as a possible direct consequence of CVT. In fact, PE has been described in CVT patients even in the absence of DVT, probably as a consequence of a detached thrombus from the lateral sinus in subjects with a global prothrombotic state in patients without thrombosis resolution. 13,14 Our study provides data that could contribute to the detection of subjects at higher risk of venous thrombotic recurrence, who may benefit from prolonged anticoagulation. Acknowledgments We are grateful to Pr Andrei V. Alexandrov for his precious comments and suggestions. None. Disclosures References 1. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352: doi: /NEJMra Lanska DJ, Kryscio RJ. Risk factors for peripartum and postpartum stroke and intracranial venous thrombosis. Stroke. 2000;31: Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35: doi: /01. STR Gosk-Bierska I, Wysokinski W, Brown RD Jr, Karnicki K, Grill D, Wiste H, et al. Cerebral venous sinus thrombosis: incidence of venous thrombosis recurrence and survival. Neurology. 2006;67: doi: /01.wnl d0. 5. Martinelli I, Bucciarelli P, Passamonti SM, Battaglioli T, Previtali E, Mannucci PM. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation. 2010;121: doi: /CIRCULATIONAHA Miranda B, Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, et al; ISCVT Investigators. Venous thromboembolic events after cerebral vein thrombosis. Stroke. 2010;41: doi: / STROKEAHA Dentali F, Poli D, Scoditti U, Di Minno MN, De Stefano V, Stefano VD, et al; Cerebral Vein Thrombosis International Study Investigators. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost. 2012;10: doi: /j x. 8. Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, et al; American Heart Association Stroke Council and the Council on Epidemiology and Prevention. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42: doi: / STR.0b013e31820a Preter M, Tzourio C, Ameri A, Bousser MG. Long-term prognosis in cerebral venous thrombosis. Follow-up of 77 patients. Stroke. 1996;27: Ferro JM, Lopes MG, Rosas MJ, Ferro MA, Fontes J; Cerebral Venous Thrombosis Portuguese Collaborative Study Group. Long-term prognosis of cerebral vein and dural sinus thrombosis. Results of the VENOPORT study. Cerebrovasc Dis. 2002;13: doi: / Hiltunen S, Putaala J, Haapaniemi E, Tatlisumak T. Long-term outcome after cerebral venous thrombosis: analysis of functional and vocational outcome, residual symptoms, and adverse events in 161 patients. J Neurol. 2016;263: doi: /s Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350: doi: /NEJMoa Diaz JM, Schiffman JS, Urban ES, Maccario M. Superior sagittal sinus thrombosis and pulmonary embolism: a syndrome rediscovered. Acta Neurol Scand. 1992;86: Cakmak S, Nighoghossian N, Desestret V, Hermier M, Cartalat-Carel S, Derex L, et al. Pulmonary embolism: an unusual complication of cerebral venous thrombosis. Neurology. 2005;65: doi: /01. wnl
Venous thrombosis in unusual sites
Venous thrombosis in unusual sites Walter Ageno Department of Medicine and Surgery University of Insubria Varese Italy Disclosures Employment Research support Scientific advisory board Consultancy Speakers
More informationLong-term outcome after cerebral venous thrombosis. Hiltunen, Sini
https://helda.helsinki.fi Long-term outcome after cerebral venous thrombosis Hiltunen, Sini 2016-03 Hiltunen, S, Putaala, J, Haapaniemi, E & Tatlisumak, T 2016, ' Long-term outcome after cerebral venous
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/188/20915 holds various files of this Leiden University dissertation. Author: Flinterman, Linda Elisabeth Title: Risk factors for a first and recurrent venous
More informationImpact of Provoking Risk Factors on the Prognosis of Cerebral Venous Thrombosis in Korean Patients
Journal of Stroke 2016;18(2):187-194 Original Article Impact of Provoking Risk Factors on the Prognosis of Cerebral Venous Thrombosis in Korean Patients Eun-Jae Lee, a Sang-Mi Noh, b Dong-Wha Kang, a Jong
More informationSaudi Journal of Medicine (SJM)
Saudi Journal of Medicine (SJM) Scholars Middle East Publishers Dubai, United Arab Emirates Website: http://scholarsmepub.com/ ISSN 2518-3389 (Print) ISSN 2518-3397 (Online) Clinical Profile and Radiological
More informationCerebral sinus-venous thrombosis (CSVT) is a rare disease
Vascular Medicine Long-Term Evaluation of the Risk of Recurrence After Cerebral Sinus-Venous Thrombosis Ida Martinelli, MD, PhD; Paolo Bucciarelli, MD; Serena M. Passamonti, MD; Tullia Battaglioli, MD;
More informationCerebral Venous-Sinus Thrombosis: Risk Factors, Clinical Report, and Outcome. A Prospective Study in the North East of Iran
Caspian Journal of Neurological Sciences http://cjns.gums.ac.ir Cerebral Venous-Sinus Thrombosis: Risk Factors, Clinical Report, and Outcome. A Prospective Study in the North East of Iran Farzadfard Mohammad-Taghi
More informationSinus and Cerebral Vein Thrombosis
Sinus and Cerebral Vein Thrombosis A Summary Sinus and cerebral vein clots are uncommon. They can lead to severe headaches, confusion, and stroke-like symptoms. They may lead to bleeding into the surrounding
More informationSinus Venous Thrombosis
Sinus Venous Thrombosis Joseph J Gemmete, MD FACR, FSIR, FAHA Professor Departments of Radiology and Neurosurgery University of Michigan Hospitals Ann Arbor, MI Outline Introduction Medical Treatment Options
More informationAre there still any valid indications for thrombophilia screening in DVT?
Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016
More informationYoung Females and Cerebral Venous Thrombosis
Article ID: WMC004294 ISSN 2046-1690 Young Females and Cerebral Venous Thrombosis Corresponding Author: Dr. Ilirjana Zekja, Neurologist, Service of Neurology- University Hospital Center 'Mother Theresa',
More informationTROMBOSIS VENOSA CEREBRAL LECCIONES DEL ISCVT
TROMBOSIS VENOSA CEREBRAL LECCIONES DEL ISCVT José M. Ferro Department of Neurociences Hospital de Santa Maria, CHLN University of Lisbon Lisboa, Portugal TROMBOSIS VENOSA CEREBRAL ISCVT LECCIONES DEL
More informationEtiology, clinical profile in cortical venous thrombosis
International Journal of Advances in Medicine Pazare AR et al. Int J Adv Med. 2018 Oct;5(5):xxx-xxx http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20183365
More informationDiagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Summary Number 68 Overview Venous thromboembolism
More informationEarly Seizures in Cerebral Vein and Dural Sinus Thrombosis Risk Factors and Role of Antiepileptics
Early Seizures in Cerebral Vein and Dural Sinus Thrombosis Risk Factors and Role of Antiepileptics José M. Ferro, MD, PhD; Patrícia Canhão, MD; Marie-Germaine Bousser, MD; Jan Stam, MD; Fernando Barinagarrementeria,
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 16 December 1999 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL
More informationCerebral venous thrombosis associated with extracranial tumours: a clinical series
Progress in Neuroscience Vol.1, N. 1-4, 2013 Original article Cerebral venous thrombosis associated with extracranial tumours: a clinical series S. IURLARO, A. SILVANI*, M. MAURI**, G. TRUCI***, S. BERETTA****,
More informationCerebral Vein and Dural Sinus Thrombosis in Elderly Patients
Cerebral Vein and Dural Sinus Thrombosis in Elderly Patients José M. Ferro, MD, PhD; Patrícia Canhão, MD; Marie-Germaine Bousser, MD; Jan Stam, MD; Fernando Barinagarrementeria, MD; for the ISCVT Investigators
More informationCerebral Venous Thrombosis (CVT): Long-Term Vocational Outcome Study. Degree project thesis in Medicine. Erik Lindgren
Cerebral Venous Thrombosis (CVT): Long-Term Vocational Outcome Study Degree project thesis in Medicine Erik Lindgren Turgut Tatlisumak Katarina Jood Department of Neurology, Sahlgrenska University Hospital,
More informationEpidemiologia e clinica del tromboembolismo venoso. Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione
Epidemiologia e clinica del tromboembolismo venoso Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione Thrombophilia may present clinically as one or more of several thrombotic manifestations
More informationCase Presentation: A 20-year-old
CLINICIAN UPDATE Cerebral Venous Thrombosis Gregory Piazza, MD, MS Case Presentation: A 20-year-old woman presented with 24 hours of severe left-sided headache associated with nausea, photophobia, and
More informationVTE in Children: Practical Issues
VTE in Children: Practical Issues Wasil Jastaniah MBBS,FAAP,FRCPC Consultant Pediatric Hem/Onc/BMT May 2012 Top 10 Reasons Why Pediatric VTE is Different 1. Social, ethical, and legal implications. 2.
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationIntrasinus Thrombolysis by Mechanical and Urokinase for Severe Cerebral Venous Sinus Thrombosis : A Case Report
122 Intrasinus Thrombolysis by Mechanical and Urokinase for Severe Cerebral Venous Sinus Thrombosis : A Case Report Wen-Sou Lin 1, Hung-Wen Kao 2, Chun-Jen Hsueh 2, Chun-An Cheng 3 Abstract- Purpose: Cerebral
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationAHA/ASA Scientific Statement
AHA/ASA Scientific Statement Diagnosis and Management of Cerebral Venous Thrombosis A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association The American
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationCerebral vein thrombosis
Intern Emerg Med (2010) 5:27 32 DOI 10.1007/s11739-009-0329-1 IM - REVIEW Cerebral vein thrombosis Francesco Dentali Walter Ageno Received: 24 March 2009 / Accepted: 3 October 2009 / Published online:
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationCerebral Vein Thrombosis: Screening of Acquired and Hereditary Thrombophilic Risk Factors
ORIGINAL REPORT Cerebral Vein Thrombosis: Screening of Acquired and Hereditary Thrombophilic Risk Factors Payam Sarraf 1, Majid Ghaffarpoor *1, Hosein Poormahmoodian 1, Hosein Harrirchian 1, and Hasan
More informationThe risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study
Journal of Thrombosis and Haemostasis, 12: 635 640 DOI: 10.1111/jth.12528 ORIGINAL ARTICLE The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationRecurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism
ARTICLES Coagulation & its Disorders Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism Tom van der Hulle, Melanie Tan, Paul L. den Exter, Mark J.G.
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationFrequency and temporal profile of recanalization after cerebral vein and sinus thrombosis
ORIGINAL ARTICLE Frequency and temporal profile of recanalization after cerebral vein and sinus thrombosis C. Herweh a, M. Griebe b, C. Geisb usch c, K. Szabo b, E. Neumaier-Probst d, M. G. Hennerici b,
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationCase Report Delay in Diagnosis of Cerebral Venous and Sinus Thrombosis: Successful Use of Mechanical Thrombectomy and Thrombolysis
Case Reports in Medicine Volume 2011, Article ID 815618, 4 pages doi:10.1155/2011/815618 Case Report Delay in Diagnosis of Cerebral Venous and Sinus Thrombosis: Successful Use of Mechanical Thrombectomy
More informationSupplementary Online Content
Supplementary Online Content Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM
More informationDave Duddleston, MD VP and Medical Director Southern Farm Bureau Life
Dave Duddleston, MD VP and Medical Director Southern Farm Bureau Life Sources of Risk for Venous Diseases Pulmonary embolism (thrombus) Bleeding from anticoagulation Mortality from underlying disease Chronic
More informationAneesh T., Hemamalini Gururaj*, Arpitha J. S., Anusha Rao, Vaishnavi Chakravarthy, Abhiman Shetty
International Journal of Research in Medical Sciences Aneesh T et al. Int J Res Med Sci. 2017 Jul;5(7):3023-3028 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20172981
More informationUnusual Deep Vein Thromboses. Dr. Karl von Kemp Centrum voor Hart- en Vaatziekten UZ Brussel
Unusual Deep Vein Thromboses Dr. Karl von Kemp Centrum voor Hart- en Vaatziekten UZ Brussel Unusual Deep Vein Thromboses Upper extremity deep vein thrombosis Spontaneous Catheter-associated Cerebral venous
More informationLong-term outcomes of patients with cerebral vein thrombosis: a multicenter study
Journal of Thrombosis and Haemostasis, 10: 1297 1302 DOI: 10.1111/j.1538-7836.2012.04774.x ORIGINAL ARTICLE Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study F. DENTALI
More informationGuidance for the management of venous thrombosis in unusual sites
J Thromb Thrombolysis (2016) 41:129 143 DOI 10.1007/s19-015-1308-1 Guidance for the management of venous thrombosis in unusual sites Walter Ageno 1 Jan Beyer-Westendorf 2 David A. Garcia 3 Alejandro Lazo-Langner
More informationIron-deficiency anemia as a rare cause of cerebral venous thrombosis and pulmonary embolism. NICASTRO, Nicolas, SCHNIDER, Armin, LEEMANN, Béatrice
Article Iron-deficiency anemia as a rare cause of cerebral venous thrombosis and pulmonary embolism NICASTRO, Nicolas, SCHNIDER, Armin, LEEMANN, Béatrice Abstract Cerebral venous thrombosis (CVT) is a
More informationThe Importance of Early Recognition of Cerebral Venous Sinus Thrombosis: A Case Report
Case Report PROVISIONAL PDF The Importance of Early Recognition of Cerebral Venous Sinus Thrombosis: A Case Report Kian Guan Goh 1, Viswanathan Shanthi 2 Submitted: 8 Sep 2014 Accepted: 2 Dec 2014 1 Faculty
More informationAyman Mahmoud Alboudi MD, MSc Rashid Hospital, Dubai, UAE
Systemic Varicella Zoster Infection Causing Cerebral Venous Thrombosis and Revealing Prothrombotic State Ayman Mahmoud Alboudi MD, MSc Rashid Hospital, Dubai, UAE CVT is a rare disorder with incidence
More informationCerebral venous and sinus thrombosis (CVST) is a relatively
Cerebral Venous and Sinus Thrombosis in Women Jonathan M. Coutinho, MD, MSc; José M. Ferro, MD, PhD; Patrícia Canhão, MD; Fernando Barinagarrementeria, MD; Carlos Cantú, MD; Marie-Germaine Bousser, MD;
More informationIschemic Stroke in Critically Ill Patients with Malignancy
Ischemic Stroke in Critically Ill Patients with Malignancy Jeong-Am Ryu 1, Oh Young Bang 2, Daesang Lee 1, Jinkyeong Park 1, Jeong Hoon Yang 1, Gee Young Suh 1, Joongbum Cho 1, Chi Ryang Chung 1, Chi-Min
More informationChapter. A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families
Chapter A higher risk of recurrent venous thrombosis in men is due to hormonal risk factors in women in thrombophilic families Willem M. Lijfering Nic J.G.M. Veeger Saskia Middeldorp Karly Hamulyák Martin
More informationUniversidade de Lisboa Faculdade de Medicina de Lisboa
Universidade de Lisboa Faculdade de Medicina de Lisboa Thrombotic recurrent events after Cerebral Vein Thrombosis Bruno Miranda Mestrado em Neurociências 2010 A impressão desta dissertação foi aprovada
More informationCerebral venous and dural sinus thrombosis
214 PRACTICAL NEUROLOGY Cerebral venous and dural sinus thrombosis José M. Ferro and Patrícia Canhão Stroke Unit, Department of Neurology, Hospital de Santa Maria, 1649 035 Lisbon, Portugal; E-mail: jmferro@iscvt.com
More informationThe Risk of Recurrent Venous Thromboembolism in Men and Women
The new england journal of medicine original article The Risk of Recurrent Venous Thromboembolism in Men and Women Paul A. Kyrle, M.D., Erich Minar, M.D., Christine Bialonczyk, M.D., Mirko Hirschl, M.D.,
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More informationRedgrave JN, Coutts SB, Schulz UG et al. Systematic review of associations between the presence of acute ischemic lesions on
6. Imaging in TIA 6.1 What type of brain imaging should be used in suspected TIA? 6.2 Which patients with suspected TIA should be referred for urgent brain imaging? Evidence Tables IMAG1: After TIA/minor
More informationDisclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
More informationPredicting the risk of recurrent venous thromboembolism (VTE)
J Thromb Thrombolysis (2015) 39:353 366 DOI 10.1007/s19-015-1188-4 Predicting the risk of recurrent venous thromboembolism (VTE) Michael B. Streiff Published online: 27 February 2015 Ó Springer Science+Business
More informationDural sinus thrombosis identified by point-of-care ultrasound
https://doi.org/10.15441/ceem.17.237 Dural sinus thrombosis identified by point-of-care ultrasound Laura T. Director, David C. Mackenzie Department of Emergency Medicine, Maine Medical Center, Portland,
More informationElevation of Blood Plasminogen Activator Inhibitor Level in Patients With Cerebral Venous Thrombosis
Original Article J Neurol Res. 2018;8(1-2):4-9 Elevation of Blood Plasminogen Activator Inhibitor Level in Patients With Cerebral Venous Thrombosis Suzan Bindal a, Ozlem Coskun b, Bulent Alioglu c, Levent
More informationCerebral venous thrombosis: An experience with anticoagulation with low molecular weight heparin
Original Article Cerebral venous thrombosis: An experience with anticoagulation with low molecular weight heparin Lalitha V. Pillai, Dhananjay P. Ambike, Satish Nirhale, S. M. K. Husainy, Satish Pataskar
More informationTHE INNOCUOUS HEADACHE THAT TURNED SINISTER
CHAPTER 54 THE INNOCUOUS HEADACHE THAT TURNED SINISTER K. RAVISHANKAR, MD Case History A 42-year-old businessman was seen in our Headache Clinic with complaints of near-daily, continuous head pain for
More informationEvaluation and managment of CVT (Continuum).pdf
University of Toronto From the SelectedWorks of Gustavo Saposnik 2015 Evaluation and managment of CVT (Continuum).pdf Gustavo Saposnik Available at: http://works.bepress.com/gustavo_saposnik/73/ Review
More informationDuration of Therapy for Venous Thromboembolism
Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee
More informationRole of MRI in Evaluation of Cerebral Venous Thrombosis
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 6 Ver. 11 (June. 2018), PP 06-12 www.iosrjournals.org Role of MRI in Evaluation of Cerebral
More informationTHROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO
THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO DISCLAIMER I m a pediatrician I will be discussing this issue primarily from a pediatric perspective
More informationCausative factors of deep vein thrombosis of lower limb in Indian population
International Surgery Jthisnal Khadilkar R et al. Int Surg J. 18 Jan;(1):3-3 http://www.ijsurgery.com pissn 39-33 eissn 39-9 Original Research Article DOI: http://dx.doi.org/1.183/39-9.isj17919 Causative
More informationAfter a first episode of acute venous thromboembolism
Predictive Value of D-Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia Gualtiero
More informationWhat is the risk of venous thromboembolism (VTE) in patients treated by an Outpatient Parenteral Antimicrobial Therapy (OPAT) Service?
What is the risk of venous thromboembolism (VTE) in patients treated by an Outpatient Parenteral Antimicrobial Therapy (OPAT) Service? David A. Barr; Sharon Irvine; Neil D. Ritchie; Jay McCutcheon; R.
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationInferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski. Department of Surgery Grand Rounds March 24, 2008
Inferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski Department of Surgery Grand Rounds March 24, 2008 History of Vena Cava Filters Virchow-1846-Proposes PE originate from veins
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/21764 holds various files of this Leiden University dissertation. Author: Mos, Inge Christina Maria Title: A more granular view on pulmonary embolism Issue
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationClinical Characteristics of Cerebral Venous Thrombosis in a Single Center in Korea
online ML Comm www.jkns.or.kr http://dx.doi.org/10.3340/jkns.2014.56.4.289 J Korean Neurosurg Soc 56 (4) : 289-294, 2014 Print ISSN 2005-3711 On-line ISSN 1598-7876 Copyright 2014 The Korean Neurosurgical
More informationEpidemiology, Endovascular Treatment, and Prognosis of Cerebral Venous Thrombosis: US Center Study of 152 Patients
Epidemiology, Endovascular Treatment, and Prognosis of Cerebral Venous Thrombosis: US Center Study of 152 Patients Kristin Salottolo, MPH; Jeffrey Wagner, MD; Donald F. Frei, MD; David Loy, MD, PhD; Richard
More informationSupplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.
Rationale, design, and baseline characteristics of the SIGNIFY trial: a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical
More informationUpdates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis. By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan
Updates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan Objectives Describe the prevalence of PE and DVT as it relates
More informationWGA meeting Management and follow-up VTE in clinical pratice Dr Borgoens CHR Citadelle Liège
WGA meeting 2016 Management and follow-up VTE in clinical pratice Dr Borgoens CHR Citadelle Liège Clinical question Which complementary investigations are you going to plan during or early after hospitalization
More informationGenetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수
Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Thrombophilia A hereditary or acquired disorder predisposing to thrombosis Questions Why should we test? Who should we test For what disorders?
More informationLow-Molecular-Weight Heparin
Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2016 Section: Prescription Drugs
More informationComputed tomography in the evaluation of cerebral venous sinus thrombosis
Computed tomography in the evaluation of cerebral venous sinus thrombosis Poster No.: C-0090 Congress: ECR 2014 Type: Authors: Keywords: DOI: Educational Exhibit J. Avsenik, K. Surlan Popovic; Ljubljana/SI
More informationInherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD
Inherited Thrombophilia Testing George Rodgers, MD, PhD Kristi Smock MD Prevalence and risk associated with inherited thrombotic disorders Inherited Risk Factor % General Population % Patients w/ Thrombosis
More informationMalignant isolated cortical vein thrombosis with type II protein S deficiency: a case report
Arai et al. BMC Neurology (2016) 16:69 DOI 10.1186/s12883-016-0597-0 CASE REPORT Open Access Malignant isolated cortical vein thrombosis with type II protein S deficiency: a case report Nobuhiko Arai *,
More informationWhat is the impact of Superficial Vein Thrombosis?
What is the impact of Superficial Vein Thrombosis? Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, University of Thessalia, Greece Chairman,
More informationDISCLOSURE. Presented by: Merav Sendowski, MD Oregon Health and Science University
Thrombophilia! DISCLOSURE Presented by: Merav Sendowski, MD Oregon Health and Science University Created by: Thomas Deloughery, MD Oregon Health and Science University Current Relevant Financial Relationship(s)
More informationA Case Report of Visual Disturbance Caused by Thrombosis of the Superior Sagittal Sinus
Journal of Analytical Oncology, 2014, 3, 41-45 41 A Case Report of Visual Disturbance Caused by Thrombosis of the Superior Sagittal Sinus Daiki Taniyama 1, Tsuyoshi Torii 2*, Junichiro Kuga 2, Yoriko Dodo
More informationΜακροχρόνια παρακολούθηση ασθενών με πνευμονική εμβολή
Μακροχρόνια παρακολούθηση ασθενών με πνευμονική εμβολή Ευφροσύνη Δ. Μάναλη Λέκτορας Β Πανεπιστημιακή Πνευμονολογική Κλινική ΓΝΑ «Αττικόν» Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών Existing guidelines
More information41 year old female with headache. Elena G. Violari MD and Leo Wolansky MD
41 year old female with headache Elena G. Violari MD and Leo Wolansky MD ? Dural Venous Sinus Thrombosis with Hemorrhagic Venous Infarct Acute intraparenchymal hematoma measuring ~3 cm in diameter centered
More informationUnderstanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
More informationCEREBRO VASCULAR ACCIDENTS
CEREBRO VASCULAR S MICHAEL OPONG-KUSI, DO MBA MORTON CLINIC, TULSA, OK, USA 8/9/2012 1 Cerebrovascular Accident Third Leading cause of deaths (USA) 750,000 strokes in USA per year. 150,000 deaths in USA
More informationCerebral venous thrombosis (CVT) is an uncommon
CLINICAL ARTICLE J Neurosurg 127:709 715, 2017 Decompressive craniectomy in hemorrhagic cerebral venous thrombosis: clinicoradiological features and risk factors *Si Zhang, MD, Hexiang Zhao, MD, Hao Li,
More informationArterial Ischemic Stroke with Protein S Deficiency in Pakistan
Case Reports Arterial Ischemic Stroke with Protein S Deficiency in Pakistan Faika Usman, Ali Hassan, Arsalan Ahmad From Section of Neurology, Department of Medicine, Shifa International Hospitals and College
More informationCASE PRESENTATION. Key Words: cerebral venous thrombosis, internal jugular vein stenosis, thrombolysis, stenting (Kaohsiung J Med Sci 2005;21:527 31)
Treatment of cerebral venous thrombosis SUCCESSFUL TREATMENT OF CEREBRAL VENOUS THROMBOSIS ASSOCIATED WITH BILATERAL INTERNAL JUGULAR VEIN STENOSIS USING DIRECT THROMBOLYSIS AND STENTING: A CASE REPORT
More informationPathological confirmation of 4 cases with isolated cortical vein thrombosis previously misdiagnosed as brain tumor
ONCOLOGY LETTERS 11: 649-653, 2016 Pathological confirmation of 4 cases with isolated cortical vein thrombosis previously misdiagnosed as brain tumor YINGXIN YU 1*, MING REN 2*, SHENG YAO 1, XIONGFEI ZHAO
More informationUpper-extremity deep vein thrombosis (DVT) is a rare
Vascular Medicine Risk Factors and Recurrence Rate of Primary Deep Vein Thrombosis of the Upper Extremities Ida Martinelli, MD, PhD; Tullia Battaglioli, MD; Paolo Bucciarelli, MD; Serena Maria Passamonti,
More informationJournal Club. 1. Develop a PICO (Population, Intervention, Comparison, Outcome) question for this study
Journal Club Articles for Discussion Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-pa Stroke Study Group. N Engl J Med. 1995 Dec
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationChapter. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy
Chapter Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy Willem M. Lijfering Min Ki ten Kate Herman G. Sprenger Jan van der Meer
More information